<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
Background Image

3D Ex Vivo Patient Tissue Platform

Moving Immuno-Oncology Models Closer to the Clinic

Despite advances in both 3D in vitro human cell-based models and in vivo animal models, 97% of oncology drugs that enter clinical trials fail to receive regulatory approval. To overcome this poor approval rate, we need patient-relevant translational systems that better mimic the heterogeneity and molecular/genetic complexity of human tumors to:

  • Understand drug effects on the native tumor microenvironment (TME)
  • Gain more accurate insights beyond general cell viability (i.e. CTG)
  • Evaluate immuno-oncology (I/O) drugs including immune checkpoint inhibitors (ICI) with endogenous immune cells

The 3D ex vivo patient tissue platform is a highly translatable screening assay for evaluating monotherapy and combination drug responses in patient tumors with endogenous immune cell populations intact. Includes the option to use in co-culture with autologous immune cells.

A Unique 3D Ex Vivo Patient Tissue Platform


Contact us to discuss your 3D Ex Vivo Patient Tissue project

Advancement Over Traditional Models

In recent years, the TME has been shown to play a crucial role in cancer progression and metastasis as well as treatment response. However, there has been a lack of research models that accurately represent the human TME. Challenges associated with traditional models include:

  • In vitro assays, such as 2D cell lines, lack the complexity and heterogeneity of patient-derived tumors and its TME.
  • In vivo models, such as PDX and GEMM, are more complex to develop and have lower throughput.

The 3D ex vivo patient tissue platform provides an alternative approach by keeping the complexity of the tumor (3D assay) and including the patient autologous TME into the assay.

Preserving Patient Tissue Biology

Make better informed decisions about progressing compounds/therapeutic candidates into the clinic with the most clinically relevant ex vivo patient tissue platform.

Comparison of Models

Attributes 2D cultures Organoids In vivo Ex vivo
Physiological complexity X ~
Throughput X ~
Translatability to the clinic X ~ ~
Study timelines ~ ~

Contact us to discuss your 3D Ex Vivo Patient Tissue project

Features Applications Readouts


  • Physiologically relevant 3D models. Understand immuno-oncology therapeutic effects on fresh patient tissue with native TME in 3D which is the most physiologically relevant preclinical environment. Preserves native TME with endogenous immune cells, fibroblasts, and other stromal components. From patients to assay plate within 24 hours.
  • Multiple readouts. Select from a variety of readouts including high content imaging for efficient combination and dosing regimen evaluations, and flow cytometry for in depth evaluation of the immune population.
  • Co-culture with autologous PBMCs available. Test your compound efficacy in an enhanced TME.
  • Reliable, reproducible data. Tumor killing and immune cell proliferation are accurately measured via phenotypic analysis to support important R&D decisions.
  • Customizable 384-well plate format (50-300 objects per well). Patient-specific plate: 50-300 patient tumor tissues directly seeded in hydrogel matrix in 384-well format.

NSCLC Response to ICI Correlates With Clinical Data1
Determine patient-specific sensitivity to immuno-oncology treatments

Evaluate Patient-to-Patient Variability
Differential Responses to SoC Drugs


Ex vivo testing protocols established for a wide range of solid tumors representing the complexity of the TME and preserving patient tumor biology.

  • Late-stage preclinical candidate evaluation 
  • Mono- and combination therapy assessment, including ICI evaluation in vitro
  • Co-culture studies
  • Potential for identifying responder/non-responder profiles
  • Potential for selection of indication for clinical trials


Multiple readouts available including:

Cytokine Analysis Confirms HCI Results
Immunotherapy responses ex vivo in NSCLC

Our ex vivo patient tissue platform is one of several high-content imaging-based screening assays offered. These include:

  • Cystic Fibrosis
  • Polycystic Kidney Disease (PKD) assay
  • Immuno-oncology assays
  • Oncology assays (cell lines and organoids)

Contact us to discuss your 3D Ex Vivo Patient Tissue project.


Discuss Your 3D Ex Vivo Patient Tissue Project

Tell us how we can help